Join the club for FREE to access the whole archive and other member benefits.

Michael Callahan

President of United Therapeutics, Division of Cellular Therapeutics and doctor at Massachusetts General Hospital.

Michael Callahan is a physician scientist boarded in medicine, ID, tropical medicine (DTM&H), Mass Casualty Care (DMC) and Rescue Medicine Command MD#17. Dr. Callahan's clinical appointments are at MGH/Harvard Medical School, and Visiting Professor at King Chulalongkorn Medical Center in Bangkok, Kaduna, Nigeria and Panama City, PN. His focus is emergency clinical trials for catastrophic infectious diseases such as Ebola, H5N1, MERS, Zika Virus, Chikungunya and complex dengue viral disease. He has developed drugs in market and expedited Phase 2 trials to support Animal Rule decisions.

In 2012 Dr. Callahan was recruited as President of Unither Virology a United Therapeutics company (UTHR), leading a R&D team executing a $45M NIH contract to accelerate a antiviral from lead to Phase 2 for dengue and flu, and to develop next-generation antivirals against RSV, Zika, Chikungunya and transplant-associated viral indications

Visit website: https://www.massgeneral.org/doctors/18760/Michael-Callahan

 michael-callahan-md-dtm-h-uk-msph-3317b890

See also: Health Organisation Massachusetts General Hospital (MGH) - Largest teaching hospital of Harvard Medical School located in Boston

Details last updated 16-Jan-2020

Michael Callahan News

China Won't Share Its Samples of a Deadly Flu Virus

Live Science - 28-Aug-2018

China refuses to share H7N9 samples making difficult developing a vaccine against it

Read more...